aripiprazole / Generic mfg. - LARVOL DELTA

Real-world adherence, healthcare resource utilization, and costs following a transition to aripiprazole once every 2 months among patients diagnosed with bipolar I disorder in the United States. (PubMed, Front Psychiatry) - "Aripiprazole monohydrate is available as LAI formulations administered once-monthly [aripiprazole once-monthly (AOM)] or once every 2 months (aripiprazole 2-month ready-to-use [Ari 2MRTU]). Inpatient visits (all-cause, BP-I-related), and all-cause LOS decreased, along with all-cause ED and total medical costs. Transitioning to Ari 2MRTU was associated with improved treatment adherence and reduced selected HCRU measures and total medical costs, supporting its value as a treatment option for BP-I."

HEOR • Journal • Real-world evidence • Bipolar Disorder • CNS Disorders • Psychiatry

Regulating the Hyperdopaminergic Substrate in Restless Legs Syndrome With Augmentation: An Open-label Study on the Safety and Efficacy of Aripiprazole. (PubMed, Clin Neuropharmacol) - "Low-dose morning aripiprazole was effective and well tolerated in patients with severe RLS and augmentation, enabling complete DA withdrawal and substantial improvement in RLS symptoms and sleep. These findings suggest that dopaminergic stabilizers could be a promising therapeutic option for RLS with augmentation. Controlled trials are warranted to confirm these results."

Journal • CNS Disorders • Fatigue • Movement Disorders • Restless Legs Syndrome • Sleep Disorder

Risk of hyperprolactinemia and extrapyramidal symptoms in antipsychotic-treated schizophrenia: a retrospective single-center real-world study. (PubMed, Front Pharmacol) - "Risperidone, paliperidone and sulpiride showed an increasing trend with elevated PRL levels, whereas quetiapine and aripiprazole were more frequently prescribed in the low-risk HPRL group. Based on homogeneous clinical real-world data, this study comprehensively evaluated multiple antipsychotic medications simultaneously. It provides empirical clinical evidence for individualized medication strategies in patients with comorbid HPRL and EPS, and offers real-world evidence for the clinical early risk recognition, and long-term medication decision-making among patients with multiple adverse reactions concurrently."

Journal • Real-world evidence • Retrospective data • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia • PRL

High Risk of Metabolic Side Effects Among New Paediatric Antipsychotic Users in Sweden-A Register-Based Study. (PubMed, Pharmacoepidemiol Drug Saf) - "The overall risk of metabolic side effects is considerable, with higher relative risks in girls, especially younger girls. These findings highlight the need for carefully considered treatment and attentive monitoring when initiating antipsychotics in children."

Adverse events • Journal • CNS Disorders • Genetic Disorders • Obesity • Pediatrics

Body Weight Changes After Switching to Lurasidone for Antipsychotic-induced Weight Gain in Bipolar Disorder: a Multicenter Retrospective Study of Selected Follow-up Cohort (clinicaltrials.gov) - P=N/A | N=155 | Completed | Sponsor: Dong-Wook Kim

New trial • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area (clinicaltrials.gov) - P=N/A | N=100 | Not yet recruiting | Sponsor: University of Alabama at Birmingham | Trial completion date: Dec 2026 ➔ Oct 2027 | Trial primary completion date: Dec 2026 ➔ Apr 2027

Adverse events • Trial completion date • Trial primary completion date • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Efficacy of Aripiprazole on Cognitive Functions in Parkinson’s Disease: A Systematic Review and Meta-analysis (MDS Congress 2026) - No abstract available

Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

A case of tic improvement following tipepidine administration in a boy with Tourette syndrome comorbid with attention-deficit/hyperactivity disorder and autism spectrum disorder. (PubMed, PCN Rep) - "The addition of tipepidine was well tolerated, and the improvement in tic symptoms was maintained during long-term follow-up. This case suggests that adjunctive tipepidine may be well tolerated and associated with sustained improvement in motor and vocal tics during long-term follow-up in a patient with TS receiving aripiprazole."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Cough • Depression • Genetic Disorders • Movement Disorders • Psychiatry • Respiratory Diseases • Tourette Syndrome

Low-Dose Clozapine Versus Aripiprazole in Borderline Personality Disorder: A Prospective Naturalistic Study. (PubMed, J Clin Psychopharmacol) - "Our results suggest that low-dose clozapine is safe and may offer superior benefits for dissociative and depressive symptoms in patients with severe BLPD. Although further research is needed, these findings highlight the role of clozapine as a valuable pharmacological option in BLPD, particularly for patients with high clinical severity and inadequate response to other antipsychotics."

Journal • Borderline Personality Disorder • CNS Disorders • Depression • Mood Disorders • Personality Disorder • Psychiatry

Retrograde Ejaculation Associated With Paliperidone Palmitate: A Case Report. (PubMed, Clin Neuropharmacol) - "Paliperidone palmitate can induce retrograde ejaculation despite its lower alpha-1 adrenergic affinity compared with risperidone. This adverse effect may be underrecognized in clinical practice and can contribute to treatment nonadherence. Proactive assessment and appropriate treatment modification are essential to improve clinical outcomes."

Journal • CNS Disorders • Sexual Disorders • ADRA1B

A TiO2@MWCNTs-based dispersive solid-phase extraction method for mitigating matrix effects in plasma LC-MS/MS analysis. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "The matrix effects of representative small-molecule drugs, including metformin, amisulpride, and aripiprazole, were compared across TiO2@MWCNTs-based d-SPE, protein precipitation, and traditional solid-phase extraction. The validated method was also successfully applied to a pharmacokinetic study of metformin with pharmacokinetic parameters comparable to those reported previously. This study shows that the dispersive solid-phase extraction method based on TiO2@MWCNTs could act as a simple, rapid, low-cost and reliable pretreatment strategy to mitigate matrix effects for small-molecule analytes with low lgP in rat plasma as a proof-of-concept attempt."

Journal

Metformin, but Not Aripiprazole, Was Associated With Attenuation of Weight Gain in Clozapine-Treated Inpatients With Concurrent Disorders: A Repeated Measures Cohort Analysis: La metformine, mais non l'aripiprazole, a été associée à une atténuation du gain de poids chez les patients hospitalisés traités par la clozapine et présentant des troubles concomi (PubMed, Can J Psychiatry) - "Metformin was associated with attenuation of weight gain over time (time × metformin: B = -2.63, 95% CI -4.49 to -0.76), whereas aripiprazole was not (B = -0.38, 95% CI -2.58 to 1.82).ConclusionMetformin was associated with attenuation of weight gain trajectory in this population, whereas aripiprazole showed no clear effect. These findings highlight substantial metabolic vulnerability in inpatient concurrent disorders settings and support early preventive metabolic interventions during clozapine treatment."

Journal • CNS Disorders • Psychiatry • Schizophrenia

A Long-Term, Open-Label, Study on Schizophrenia (clinicaltrials.gov) - P2/3 | N=560 | Terminated | Sponsor: Denovo Biopharma LLC | N=1210 ➔ 560

Enrollment change • CNS Disorders • Psychiatry • Schizophrenia

Diagnosis of Antipsychotic Medication-Induced Severe Hypertriglyceridaemia by the Phenomenon of Pseudohyponatraemia and Successful Management With Variable-Rate Intravenous Insulin Infusion: A Case Report. (PubMed, Case Rep Endocrinol) - "Acute pancreatitis did not develop during the inpatient admission or during outpatient follow-up, and triglyceride levels have fallen substantially (3.2 mmol/L at 5 months) having been switched from quetiapine and risperidone to aripiprazole, an SGA associated with less metabolic disturbance. This case demonstrates the safe and effective management of SGA-associated severe HTG with intravenous insulin infusion to prevent acute pancreatitis. It also highlights the utility of pseudohyponatraemia as a useful way of detecting severe HTG and the impact of SGA medications in the aetiology of severe HTG."

Journal • CNS Disorders • Diabetes • Dyslipidemia • Mental Retardation • Metabolic Disorders • Pancreatitis • Psychiatry • Severe Hypertriglyceridemia

The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression. (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: Washington University School of Medicine

New P2 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Summary for Non-Psychiatrists of the Australian and New Zealand Journal of Psychiatry Grading of Recommendations, Assessment, Development and Evaluations (GRADE) Guidelines for the Management of Schizophrenia. (PubMed, Med J Aust) - "A comprehensive yet tailored clinical assessment should be undertaken to identify treatable physical health comorbidities early, particularly for people with early psychosis. Pharmacotherapy should aim for the lowest effective dose with a tolerable and manageable adverse-effect profile (e.g., first-line pharmacotherapy with aripiprazole, brexpiprazole, cariprazine or lurasidone). Lifestyle interventions, particularly physical activity and multimodal lifestyle programmes, should be routinely offered to people with schizophrenia. Psychological and psychosocial interventions are essential components of care for people with schizophrenia, especially during the maintenance phase of illness. Clinicians should actively involve people with schizophrenia and their family, whānau and carers in shared decision-making. Comorbid psychiatric symptoms and conditions should be assessed and managed according to standard treatment approaches until more robust evidence base specific to..."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Antipsychotic-associated obsessive-compulsive symptoms and disorder: scoping review of mechanisms, comparative epidemiology and clinical implications. (PubMed, BJPsych Open) - "Evidence for inducing obsessive-compulsive symptoms varies across antipsychotics, being most consistent for clozapine and least for predominantly dopamine-blocking agents. Brief routine screening and a pragmatic response pathway may be considered in clozapine services, with vigilance for other agents as evidence accrues."

Journal • Review • CNS Disorders • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

Dose-Dependent Efficacy of Aripiprazole in Jealous-Type Delusional Disorder: A Case Study Guided by PSYRATS-DS. (PubMed, J Clin Psychopharmacol) - No abstract available

Journal

Drug utilisation and adverse drug reaction monitoring in schizophrenic patients: A tertiary care hospital study in India. (PubMed, Bioinformation) - "Significant dose variations were noted in commonly used antipsychotics such as risperidone, olanzapine and aripiprazole, as well as benzodiazepines like clonazepam and lorazepam (p<0.001). Atypical antipsychotics predominated due to better tolerability and lower extrapyramidal side effects, highlighting evolving prescribing trends. Thus, structured evidence on drug utilization patterns and variability in dosing, help in optimizing rational prescribing practices in schizophrenia management."

Adverse drug reaction • Journal • CNS Disorders • Psychiatry • Schizophrenia

Risperidone-Induced Nasal Congestion and Increased Urinary Frequency. (PubMed, Cureus) - "Risperidone was subsequently discontinued and replaced with aripiprazole. This case suggests a probable association between risperidone and the development of nasal congestion and urinary frequency. Awareness of these uncommon adverse effects may help clinicians identify medication-related symptoms, avoid unnecessary investigations, and improve treatment adherence."

Journal • CNS Disorders • Otorhinolaryngology • Psychiatry

Clinical Use of Aripiprazole Monohydrate Long-Acting Injectable in Adolescents: A Case Series and Review of the Literature. (PubMed, Int J Psychiatry Med) - "No serious adverse effects were reported.ConclusionAM LAI appears to be a safe and effective off-label treatment option in high-risk adolescents with poor adherence to oral antipsychotics. This case series contributes clinically relevant real-world data to the limited literature on LAI use in pediatric psychiatry."

Journal • CNS Disorders • Mental Retardation • Pediatrics • Psychiatry • DRD2

Interim data from ENIGMA – TRS 1 study of evenamide as add on therapy to antipsychotic Standard of Care in patients with treatment resistant schizophrenia (TRS). Difficulties in performing TRS study with TRRIP criteria: the CRO experience (WFSBP 2026) - "One aspect of the ENIGMA – TRS 1 study assesses plasma concentrations of standard of care as selected antipsychotics: Aripiprazole, Brexpiprazole, Cariprazine, Clozapine, Lurasidone, Olanzapine, Paliperidone, Quetiapine, Risperidone and Ziprasidone for subjects treated with those antipsychotics with daily therapeutic doses meeting local product labels requirements and correlated those with minimal duration of 6 weeks treatment with any of those medications. As the study is performed in 20 countries worldwide major issues reside in getting approval by all regulatory approvals, languages use for the rating instruments as well as for the training of the raters. Based on hundreds of patients entering screening, a large proportion failed the screening phase because of lack of adequate concentration of the primary AP. Difficulties have been noticed in ensuring adequate documentation of previous AP failures."

Clinical • CNS Disorders • Psychiatry • Schizophrenia

Retraction: Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. (PubMed, PLoS One) - No abstract available

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Structured management of dopamine agonist withdrawal in restless legs syndrome with augmentation: A prospective real-world cohort study. (PubMed, Sleep Med) - "A structured protocol achieved complete DA withdrawal in the majority of patients within one month, with short-term clinical improvement. Early management of augmentation improves the likelihood of successful withdrawal."

Journal • Real-world evidence • Movement Disorders • Restless Legs Syndrome • Sleep Disorder

Real-world adherence and healthcare resource utilization following transition to aripiprazole once-every-2-months from oral or once-monthly aripiprazole among patients diagnosed with schizophrenia in the United States. (PubMed, Curr Med Res Opin) - "All-cause LOS was lower post- versus pre-transition (0.64 ± 2.63 vs 1.05 ± 3.93 days, p = 0.047). Transitioning to Ari 2MRTU was associated with significantly improved adherence and reductions in certain HCRU measures in patients diagnosed with schizophrenia."

HEOR • Journal • Real-world evidence • CNS Disorders • Psychiatry • Schizophrenia